| 摘要 |
Disclosed is the use of CD10+, CD34–, CD105+, CD200+ placental stem cells in the manufacture of a medicament for treating an individual having a disease or disorder of the circulatory system, wherein said treating results in a detectable improvement of one or more symptoms of said disease or disorder. Further disclosed is the use of CD10+, CD34–, CD105+, CD200+ placental stem cells in the manufacture of a medicament for treating an individual having a disruption of blood flow in or around a limb, wherein said treating results in a detectable improvement of one or more symptoms caused by said disruption of blood flow. |
